DaVita's (DVA, $59.31) Q2 operating income outlook comes in higher than expected
Shares of DaVita surged more than +5% in premarket trading Monday, following news of the company’s second-quarter operating income guidance exceeding analysts’ expectations.
The healthcare company reported its projection for second-quarter operating income between $460 million and $465 million - a range that is substantially higher than the FactSet consensus of $398 million.
For the full-year, the company increased its adjusted operating income guidance to between $1.64 billion and $1.70 billion, from its prior forecast of a range of $1.54 billion to $1.64 billion.
The news comes ahead of DaVita’s modified Dutch auction tender offer on up to $1.2 billion of its common stock. The auction, priced between $53.50 and $61.50 per share, will start on Monday and continue until August 16 midnight.
DVA in upward trend: 10-day moving average crossed above 50-day moving average on April 30, 2026
The 10-day moving average for DVA crossed bullishly above the 50-day moving average on April 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 28, 2026. You may want to consider a long position or call options on DVA as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DVA just turned positive on April 29, 2026. Looking at past instances where DVA's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
DVA moved above its 50-day moving average on April 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 218 cases where DVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DVA broke above its upper Bollinger Band on May 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. DVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (91.743) is normal, around the industry mean (136.814). P/E Ratio (18.553) is within average values for comparable stocks, (100.254). Projected Growth (PEG Ratio) (0.598) is also within normal values, averaging (2.446). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (1.013) is also within normal values, averaging (2.408).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement
Advertisement